The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)
Open accessAbstract
Introduction: Immunohistochemistry of primary breast cancer is routinely used to guide changes in therapy at the time of relapse. Retrospective reviews suggest that the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor type 2 (HER2) receptor may differ between the primary and loco-regional recurrence or distant metastases. The Breast Recurrence In Tissues Study (BRITS) was a large, multicentre, prospective study to examine changes in ER, PR and HER2. Methods: Matched primary and recurrent breast cancer tissue samples were prospectively collected from 205 women attending 20 institutions. Central laboratory immunohistochemical analysis of core biopsies and tissue microarrays of ER and PR using the Allred and Quickscore methods and HER2 (confirmed by fluorescence in situ hybridisation (FISH) for HER2 2+) were performed. Results: From 205 consenting women, 18 (8.8%) did not have recurrent disease on biopsy, 35 were ineligible, 13 had insufficient paired tissue and 2 were excluded for safety reasons. Paired samples from 137 women, mean age 62.6 years (range 27-87 years), 83/137 (60.6%) postmenopausal with a median 92.2 months (range 5-327 months) from primary to recurrence and 88 (64.2%) as locoregional recurrence were successfully analysed. A switch in receptor status, in either direction, by Allred score, was identified for ER in 14 patients (10.2%; P = 0.983 Wilcoxon sign rank test), PR in 34 (24.8%; P = 0.003 Wilcoxon sign rank test) and HER2 in 4 (2.9%; P = 0.074 Wilcoxon sign rank test). There was no difference between locoregional or distant recurrence in the proportion who switched. The switch in receptor status led to a change in the subsequent treatment plan for 24 patients (17.5%). Conclusions: This prospective study confirms retrospective evidence that the management of relapsed breast cancer should include confirmatory tissue sampling and identify switches of ER, PR or HER2 which change therapeutic management for one in six patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,056
Detre, S., Saclani Jotti, G., & Dowsett, M. (1995) · Journal of Clinical Pathology · doi:10.1136/jcp.48.9.876 · Cited by 880
Current issues in ER and HER2 testing by IHC in breast cancer
Gown, A. M. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.34 · Cited by 374
Kuukasjärvi, T., Kononen, J., Helin, H., Holli, K., & Isola, J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.9.2584 · Cited by 358
Johnston, S. R. D., Saccani‐Jotti, G., Smith, I. E., Salter, J., Newby, J. C., Coppen, M. J., Ebbs, S. R., & Dowsett, M. (1995) · PubMed · Cited by 301
Simmons, C., Miller, N., Geddie, W., Gianfelice, D., Oldfield, M., Dranitsaris, G., & Clemons, M. J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp028 · Cited by 286
Liedtke, C., Broglio, K., Moulder, S., Hsu, L., Kau, S.-W., Symmans, W. F., Albarracin, C., Meric-Bernstam, F., Woodward, W., Theriault, R. L., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp263 · Cited by 286
A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer Biomarkers
Camp, R. L., Neumeister, V., & Rimm, D. L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3567 · Cited by 275
Carlsson, J., Nordgren, H., Sjöström, J., Wester, K., Villman, K., Bengtsson, N. O., Ostenstad, B., Lundqvist, H., & Blomqvist, C. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601881 · Cited by 225
Wu, J. M., Fackler, M. J., Halushka, M. K., Molavi, D. W., Taylor, M. E., Teo, W. W., Griffin, C., Fetting, J., Davidson, N. E., De Marzo, A. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4082 · Cited by 202
Cited by
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Tumour heterogeneity in the clinic
Bedard, P. L., Hansen, A. R., Ratain, M. J., & Siu, L. L. (2013) · Nature · doi:10.1038/nature12627 · Cited by 1,211
Rugo, H. S., Rumble, R. B., Macrae, E., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L., Fowble, B., Ingle, J. N., Jahanzeb, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1487 · Cited by 633
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu385 · Cited by 540
“LoE changed since ABC1 from 2C to 1C based on new published data [128–130].”
Lindström, L. S., Karlsson, E., Wilking, U. M., Johansson, U., Hartman, J., Lidbrink, E. K., Hatschek, T., Skoog, L., & Bergh, J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2482 · Cited by 523
Amir, E., Miller, N., Geddie, W., Freedman, O., Kassam, F., Simmons, C., Oldfield, M., Dranitsaris, G., Tomlinson, G., Laupacis, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5232 · Cited by 434
“These findings are similar to those published previously.(7,8,20,21) No baseline factors were identified that increased the likelihood of change in therapy, although triple-negative tumors tended not to be discordant.”
Eccles, S. A., Aboagye, E. O., Ali, S., Anderson, A. S., Armes, J., Berditchevski, F., Blaydes, J. P., Brennan, K., Brown, N. J., Bryant, H. E., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3493 · Cited by 421
Self-citationNiikura, N., Liu, J., Hayashi, N., Mittendorf, E. A., Gong, Y., Palla, S. L., Tokuda, Y., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Ueno, N. T. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8889 · Cited by 410
Van Poznak, C., Somerfield, M. R., Bast, R. C., Cristofanilli, M., Goetz, M. P., Gonzalez-Angulo, A. M., Hicks, D. G., Hill, E. G., Liu, M. C., Lucas, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.1459 · Cited by 404
Sinn, B. V., Fu, C., Lau, R., Litton, J., Tsai, T.-H., Murthy, R., Tam, A., Andreopoulou, E., Gong, Y., Murthy, R., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0111-0 · Cited by 354
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · The Breast · doi:10.1016/j.breast.2014.08.009 · Cited by 338
Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
Schrijver, W. A. M. E., Suijkerbuijk, K. P. M., van Gils, C. H., van der Wall, E., Moelans, C. B., & van Diest, P. J. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx273 · Cited by 306
Aurilio, G., Disalvatore, D., Pruneri, G., Bagnardi, V., Viale, G., Curigliano, G., Adamoli, L., Munzone, E., Sciandivasci, A., De Vita, F., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.10.004 · Cited by 292
Molecular classification of breast cancer
Vuong, D., Simpson, P. T., Green, B., Cummings, M. C., & Lakhani, S. R. (2014) · Virchows Archiv · doi:10.1007/s00428-014-1593-7 · Cited by 262
Metadata
- Authors
- Thompson, A. M., Jordan, L. B., Quinlan, P., Anderson, E., Skene, A., Dewar, J. A., Purdie, C. A., & the Breast Recurrence in Tissues Study Group
- Venue
- Breast Cancer Research
- Published
- 2010-11-08
- Volume
- 12
- Issue
- 6
- Pages
- R92-R92
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2144396863
- Cited by
- 253
- References
- 24
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.